Aytu BioPharma - AYTU Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" AYTU shares.
View AYTU analyst ratings or view top-rated stocks.

1 analysts have issued 1 year price objectives for Aytu BioPharma's stock. Their AYTU share price forecasts range from $5.00 to $6.00. On average, they predict the company's share price to reach $5.50 in the next year. This suggests a possible upside of 2,800.8% from the stock's current price.
View analysts price targets for AYTU or view top-rated stocks among Wall Street analysts.

Aytu BioPharma's stock was trading at $1.35 at the start of the year. Since then, AYTU stock has decreased by 86.0% and is now trading at $0.1896.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our AYTU earnings forecast.

Aytu BioPharma, Inc. (NASDAQ:AYTU) issued its quarterly earnings data on Tuesday, September, 27th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.01. The business had revenue of $27.45 million for the quarter, compared to the consensus estimate of $25.70 million. Aytu BioPharma had a negative net margin of 83.18% and a negative trailing twelve-month return on equity of 47.20%.

Aytu BioPharma's stock reverse split on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aytu BioPharma investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), ADMA Biologics (ADMA), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), iBio (IBIO), Matinas BioPharma (MTNB), Bionano Genomics (BNGO) and SCYNEXIS (SCYX).

Aytu BioPharma trades on the NASDAQ under the ticker symbol "AYTU."

Aytu BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.80%), Vanguard Group Inc. (1.56%), Commonwealth Equity Services LLC (0.34%) and Prudential Financial Inc. (0.23%). Insiders that own company stock include Armistice Capital Master Fund, Armistice Capital, Llc and Joshua R Disbrow.
View institutional ownership trends.

Shares of AYTU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AYTU stock can currently be purchased for approximately $0.19.

Aytu BioPharma (NASDAQ:AYTU) has a market capitalization of $11.84 million and generates $96.67 million in revenue each year. The company earns $-110,170,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis.

The company employs 175 workers across the globe.

Aytu BioPharma's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The official website for the company is aytubio.com. The company can be reached via phone at (720) 437-6580 or via email at james@haydenir.com.